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Although vaccines have proven pivotal against arrays of infectious viral diseases, there
are still no effective vaccines against many viruses. New structural insights into the
viral envelope, protein conformation, and antigenic epitopes can guide the design of
novel vaccines against challenging viruses such as human immunodeficiency virus (HIV),
hepatitis C virus, enterovirus A71, and dengue virus. Recent studies demonstrated that
applications of this structural information can solve some of the vaccine conundrums.
This review focuses on recent advances in structure-based vaccine design, or structural
vaccinology, for novel and innovative viral vaccine design.
Keywords: structural vaccinology, vaccine design, protein structure, epitope, virus
INTRODUCTION
Vaccination has considerably reduced morbidity and mortality caused by viruses such as smallpox
virus and poliovirus. However, there remain many viruses without effective vaccines including
dengue virus, human immunodeficiency virus (HIV), enterovirus A71, and hepatitis C virus.
In addition, emerging infectious diseases will continue to threaten public health. Therefore,
rapid vaccine development is mandatory to prevent pandemics. Currently, there are only 17
licensed vaccines in the United States against 13 viruses. These vaccines are either live-attenuated
vaccines (11 vaccines), whole-inactivated vaccines (4 vaccines), or virus-like particle vaccines (2
vaccines) (Graham and Sullivan, 2018). Notably, the inactivated and live-attenuated vaccines are
based on technologies developed decades ago. Taking live-attenuated vaccines as an example, the
development of this type of vaccine is empirical and time-consuming. The virulent virus will
be passaged in either tissue cultures or live animals until the avirulent form was isolated. In
the settings of challenging viruses, these traditional approaches have failed to produce effective
vaccines. Additionally, traditional approaches would not be swift enough to respond to epidemics
caused by emerging viruses. This is due to lack of knowledge and experience with viral pathogenesis,
viral growth, and attenuating determinants of the emerging viruses (Graham and Sullivan, 2018).
Therefore, the focus for vaccine development against challenging viruses should be based on newer
rational vaccine design platforms. In this article, we will cover recent advances in the development
of novel vaccines facilitated by structural vaccinology. Additionally, we will discuss how structural
vaccinology could lead to the discovery of antibodies for passive immunization. Finally, we will
provide suggestions of how structural vaccinology can be exploited for future vaccine design.
STRUCTURAL VACCINOLOGY APPROACH
Structural biology approaches have enabled the determination of the structure of
whole viruses, viral proteins, and antigen–antibody complexes (Kaufmann et al., 2010;
Lee and Wilson, 2015; Anasir et al., 2017a,b). The three-dimensional (3D) structures
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provide crucial insights into the tertiary structure and
position of the viral epitopes. Ultimately, the detailed
structural information can be exploited to solve some of
the challenging problems impeding vaccine development
against viruses. Structural vaccinology is a rational approach
to generate an effective vaccine that involves (1) determining
the atomic structure of the antigen or antigen–antibody
complex, (2) remodeling the antigen or the epitope by reverse
molecular engineering, (3) incorporating the re-engineered
antigen or epitope into one of the vaccine platforms, and
(4) testing the safety and efficacy of the candidate vaccine
in vivo (Figure 1).
In the first step of this approach, the 3D structure of
the antigen or antigen–antibody complex will be determined
using either one or more of the structural biology tools
such as X-ray crystallography, cryo-electron microscopy, and
nuclear magnetic resonance. Thereafter, the antigen will be
remodeled based on the structural information of the antigen.
In addition, the immunological and bioinformatics knowledge
should be synergistically combined with the structural insights
to design an effective antigen. In most cases, the re-engineering
process involves mutations of certain amino acids to stabilize
immunogenic conformations, mask unwanted non-neutralizing
antibody epitopes, optimize antigen thermostability, or introduce
additional epitopes on the antigen. Next, the re-engineered
antigen could be incorporated into one of the vaccine
platforms such as the recombinant protein vaccine, the virus-
like particle vaccine, or the live-attenuated vaccine. Finally,
the immunogenicity and efficacy of the candidate vaccine
should be tested in animal models including mice, ferrets,
and macaques. Based on the preclinical findings, the candidate
vaccine could be redesigned to improve its immunogenicity
and efficacy. Structural vaccinology was shown to be successful
in overcoming the challenges facing the bacterial vaccine field.
For instance, the 3D structures of H-binding protein of Men
B and the pili of group B Streptococcus have facilitated the
design of improved vaccines (Van Regenmortel, 2016). Similarly,
structural vaccinology has been used to improve the efficacy
of viral vaccines.
HUMAN IMMUNODEFICIENCY VIRUS
Human immunodeficiency virus is a serious public health
threat with more than 35 million people living with HIV/AIDS
worldwide in 2017. To date, there are no effective vaccines
or drugs against HIV. Major barriers to vaccine development
include the extreme diversity of HIV strains and the high
malleability of its envelope. Due to these barriers, protective
immune responses against HIV tend to be polyclonal and involve
antibodies directed to a plethora of epitopes. Having structural
information for the variable antigens in the viral envelopes
is essential to design a vaccine that can elicit potent broadly
neutralizing antibodies. HIV is one of the most studied pathogens
in the context of structural vaccinology application. However,
the development of an effective vaccine against HIV through a
structural vaccinology approach remains elusive.
Modification of Envelope
Glycoprotein gp120
The glycoprotein (gp) 120 that is present on the surface of
the HIV envelope has been identified as the main target for
neutralizing antibodies (Pantophlet and Burton, 2006). However,
its variability and malleable nature contribute to host immune
evasion (Chen et al., 2009). Several groups have reported the
development of structure-based vaccine candidates based on the
modified gp120. For instance, structure-based modifications of
gp120 significantly stabilized its core domain at the co-receptor
binding site (Dey et al., 2009). Subsequent immunization studies
revealed that the conformational stabilization was associated with
increased humoral immune responses targeting the stabilized
site. Although the initial modifications were unsuccessful to
produce an effective vaccine against HIV, the study initiated
the screening for broadly neutralizing antibodies against re-
engineered gp120 proteins (Wu et al., 2010; Huang et al., 2018).
Another major barrier to HIV vaccine development is the
induction of non-neutralizing antibodies by numerous epitopes
on its envelope (McGuire et al., 2014). Such antibodies could
hinder the function of its broadly neutralizing counterparts. The
V3 loop of gp120 is an example of a non-neutralizing antibody
epitope. Previous studies revealed that V3 immunogenicity
could be diminished by introducing a hydrophobic amino acid
substitution (A316W mutation) to reduce its conformational
flexibility (de Taeye et al., 2015). Recently, two hydrophobic
mutations, S306L and R308L, were found to further stabilize
the V3 region, potentially by maintaining the burial of the
V3 region in the pocket formed by V1/V2 domains (de Taeye
et al., 2018). Binding studies showed that these hydrophobic
mutations impaired non-neutralizing antibody interactions with
the V3 loop. Immunization studies in rabbits revealed that
the stabilization of the V3 region was associated with reduced
induction of non-neutralizing antibodies, while the induction
of neutralizing antibodies remained the same. These data
demonstrated that structural vaccinology could be exploited to
reduce the induction of non-neutralizing antibodies.
Stabilization of Prefusion-Closed
HIV Envelope
Human immunodeficiency virus envelope in its prefusion-closed
state is the main target of broadly neutralizing antibodies
(Wang et al., 2016; Ozorowski et al., 2017). Due to the
extreme diversity of HIV strains, sequential immunization with
HIV envelopes adopting the prefusion-closed conformation
from different strains might be needed to induce sufficiently
broadly neutralizing antibodies. Despite many attempts to
stabilize the HIV envelope in its prefusion-closed state, these
variants were found to fluctuate between closed and open
prefusion states (Ozorowski et al., 2017). Recently, Rutten et al.
(2018) described a universal approach to produce high-quality
prefusion-closed HIV envelopes through a repair-and-stabilize
approach (Rutten et al., 2018). In the repair stage, they substituted
rare strain-specific residues of the envelopes with more prevalent
residues. In the stabilization stage, regions crucial for envelope
refolding were modified to increase stability. One of the variants
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FIGURE 1 | Structural vaccinology for vaccine design. (A) Basic methods and tools for structural vaccinology. (B) Irreversible conformational change (immunogenic
to non-immunogenic) of viral antigens occurred spontaneously during recombinant antigen expression. To overcome this problem, the three-dimensional structure of
the antigen (II) will be determined using structural biology techniques such as X-ray crystallography, cryo-electron microscopy (cryo-EM), and nuclear magnetic
resonance (NMR). Based on the structure, the antigen will be re-engineered to produce an optimal antigen adopting a specific immunogenic conformation (I). Next,
the re-engineered antigen could be incorporated into one of the vaccine platforms such as the recombinant protein vaccine platform. Thereafter, the safety and
efficacy of the candidate vaccine should be tested in animal models. The antigen could be re-designed based on the animal testing evaluations to improve its
immunogenicity and efficacy. RSV F glycoprotein was used as an illustrative example. PDB IDs: 4MMU and 3RKI.
designated as ConC_base0, which carried seven stabilizing
substitutions, was found to be stable at 37◦C for 4 weeks. This
variant exhibited increased binding toward broadly neutralizing
antibodies along with reduced affinity toward non-neutralizing
antibodies. Detailed inspection of the variant structure revealed
that the inter- and intra-protomer stabilizing mutations provided
synergistic effect to stabilize the envelope in the prefusion-closed
structure. Hence, this approach may be a better strategy to
generate high-quality prefusion-closed HIV envelopes for future
development of efficacious vaccines against HIV.
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Monoclonal Antibodies for Passive
Immunization Against HIV
The screening of broadly neutralizing antibodies against HIV
was initiated by the structural determination of the gp120–CD4
receptor complex (Kwong et al., 1998). Earlier, the attempts
to generate broadly neutralizing antibodies specifically directed
toward the CD4 binding site were unsuccessful. The failure was
partly due to the fact that the gp120 used in the screening
was reactive with many other antibodies, including the non-
neutralizing antibodies. To generate specific antibodies targeting
the CD4 binding site, gp120 was modified to eliminate the
other antigenic regions while preserving the CD4 binding site
(Wu et al., 2010). One of the variants designated as resurfaced
stabilized core 3 (RSC3) was chosen to be used in the screening of
broadly neutralizing monoclonal antibodies. From the screening,
three monoclonal antibodies, which are VRC01, VRC02, and
VRC03, were found to bind strongly and specifically to RSC3.
VRC01 displayed impressive breadth of reactivity by neutralizing
91% of the 190 circulating HIV-1 genetic subtypes. Subsequent
structural studies revealed that VRC01 engaged the CD4 binding
site of gp120 in a similar manner to the CD4–gp120 interactions
(Zhou et al., 2010). Currently, VRC01 is in the phase II clinical
trial as a passive immunization strategy (Huang et al., 2018).
HEPATITIS C VIRUS
Hepatitis C virus is the leading cause of liver diseases such
as cirrhosis, liver failure, and liver cancer. More than 64
million people are chronically infected with hepatitis C virus
(Manns et al., 2017). Liver transplantation is the main treatment
undertaken for those with cirrhosis and liver cancer (Manns
et al., 2017). However, the treatment does not fully eliminate
the virus, resulting in possible viral rebound and infection of the
transplanted liver (Manns et al., 2017). High cost is also associated
with other antiviral treatments (Cox, 2015), underscoring the
importance of developing a vaccine against hepatitis C virus.
Epitope-Based Vaccines Against
Hepatitis C Virus
Similar to HIV, the development of a vaccine against hepatitis
C virus has been hampered by the variability and diversity of
target antigens. E2 glycoprotein is the main target for hepatitis
C vaccine development. To date, the structure of full-length
E2 has yet to be determined (Pierce et al., 2017). Importantly,
two crystallographic structures of the engineered E2 core from
two genotypes are available (Kong et al., 2013; Khan et al.,
2014). In addition, various structures of hepatitis C viral antigens
in complexes with broadly neutralizing antibodies have been
determined (Kong et al., 2012a,b, 2015; Deng et al., 2013; Krey
et al., 2013; Meola et al., 2015). These studies identified multiple
epitopes that could elicit broadly neutralizing antibodies. One
of the epitopes, designated as epitope I, is located near the
N-terminus of E2. The epitope was found to elicit arrays of
human (Keck et al., 2013) and murine antibodies (Tarr et al.,
2006). Structural studies revealed that epitope I adopted a
β-hairpin fold when bound to neutralizing antibodies (Kong
et al., 2012b; Sandomenico et al., 2016).
Initially, a cyclic variant of epitope I adopting the β-hairpin
fold was designed to generate and characterize monoclonal
antibodies specific against the epitope variant (Sandomenico
et al., 2016). This antigen was able to elicit antibodies in mice.
However, the antibodies lacked neutralization activity when
tested. Subsequently, Pierce et al. (2017) designed cyclic antigens
to stably present epitope I in its antibody-bound conformation
using the natural scaffold approach (Pierce et al., 2017). They
identified θ-defensin protein, which adopted the β-hairpin
substructure nearly identical to the antibody-bound epitope I
structure (Conibear et al., 2013). Based on the cyclic θ-defensin
structure, they designed two cyclic epitope I antigens comprising
minimal scaffolded structures of the epitope. Immunogenicity
studies revealed that the cyclic antigens induced higher epitope-
specific serum responses in comparison to the linear peptide.
Subsequent viral neutralization studies indicated that the cyclic
antigens were superior immunogens than the linear epitope.
However, the antibody responses elicited by the cyclic antigens
were still low. Various options are available to improve cyclic
epitope 1 immunogenicity. For instance, the cyclic antigens could
be displayed on a virus-like particle or other nanoparticles to
enhance immune responses against them.
In another approach, Pierce et al. (2017) designed a bivalent
truncated E2 antigen displaying two copies of epitope I on
its surface. By analyzing E2 core structures, they identified
a site suitable to display the second epitope I. However, the
bivalent antigen elicited lower neutralizing antibody responses
than its monovalent counterpart. This indicated that further
understanding of the host humoral responses against E2 is
required for successful vaccine design in the future.
RESPIRATORY SYNCYTIAL VIRUS
Respiratory syncytial virus (RSV) is an etiological agent that
causes lower respiratory tract infection in infants and children
and often leads to hospitalizations. Previously, a formaldehyde-
inactivated RSV vaccine candidate was found to enhance the
disease upon subsequent infection with the wild-type virus,
while live-attenuated vaccine development has yet to unearth an
acceptable balance of RSV attenuation (Moghaddam et al., 2006).
Prefusion F Stabilization
F glycoprotein is an attractive antigen for vaccine development
as it contains multiple neutralizing epitopes. The protein forms
a lollipop-shaped structure with its C-terminus inserted into
the virion membrane. During viral entry, it rearranges from
a metastable prefusion state to a highly stable postfusion
state (Figure 2). Previous studies revealed that the metastable
prefusion state accounted for most of the neutralizing activity
(Magro et al., 2012). Moreover, McLellan et al. (2013b) identified
an antigenic site that was bound by several prefusion F-specific
antibodies. The antigenic site  is located at the top of the
prefusion F trimer and is readily accessible by the antibodies
even on the crowded virion surface. The prefusion F was also
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FIGURE 2 | Targeting the prefusion F glycoprotein of respiratory syncytial virus
(RSV). (A) Surface representation of the DS-Cav1 F glycoprotein variant (PDB
ID: 4MMU). DS-Cav1 adopted the prefusion F glycoprotein conformation. The
antigenic site  is shown in black. (B) Surface representation of the trimeric
postfusion F glycoprotein (PDB ID: 3RKI). The disrupted antigenic site 
caused by structural rearrangement from the prefusion to postfusion F is
shown in black.
found to be the target of RSV-neutralizing activity in human sera.
Importantly, the antigenic site  is only present on prefusion F
and not on the postfusion F antigen (Steff et al., 2017).
To identify the prefusion F with the highest stability at the
antigenic site , McLellan et al. (2013a) produced over 100
variants of the protein. These variants possessed mutations either
to stabilize the antigenic site or to destabilize the postfusion F.
From the study, they identified a variant favoring the prefusion
conformational state designated as DS-Cav1. DS-Cav1 carried
S155C-S209C double mutations to form a disulfide bond and
cavity-filling mutations (S190F and V207L). Studies in mice,
macaques, and calves revealed that DS-Cav1 elicited potent
neutralizing responses (McLellan et al., 2013a; Steff et al., 2017).
Crucially, the studies using calves concluded that the use of DS-
Cav1 was able to extend the duration of protection conferred by
maternal immunization, potentially lowering RSV disease burden
in infants (Steff et al., 2017). In 2017, DS-Cav1 entered phase I
clinical trial and the trial is currently ongoing.
INFLUENZA A VIRUS
Influenza causes significant disease and death in the human
population especially among the young and elderly (Shao
et al., 2017). Currently, individuals are vaccinated with seasonal
influenza vaccine that stimulates humoral immune responses
toward the globular head domain of the viral hemagglutinin
(HA). HA is a glycoprotein that acts as a mediator of viral entry
into host cells (Sautto et al., 2018). One major problem with the
current vaccine is that the antibodies elicited are highly strain
specific, as the globular head domain is not conserved across
strains. Therefore, the vaccines must be reformulated annually
based on the anticipated influenza strain. Furthermore, most
influenza vaccines are produced in an egg-based production
system. Previous study showed that this production system
caused amino acid substitutions on the HA during passaging and
led to reduction in vaccine efficacy (Wu et al., 2017). In addition,
the production process is slow and can cause severe production
bottleneck during an epidemic.
Universal Influenza Vaccine
Many investigators characterized antibody–HA complexes to
elucidate the host humoral immune responses against influenza
A. Corti et al. (2011) identified a broad neutralizing antibody
targeting the F subdomain within the highly conserved stem
domain of HA. Subsequent comprehensive sequence analysis
revealed a high degree of conservation within the stem domain,
unlike the variable head domain (Mallajosyula et al., 2015).
More recently, evolutionary analysis indicated that the stem
domain evolved slowly over time than the evolution of the
head domain (Kirkpatrick et al., 2018). In addition, the study
found that the stem evolution did not aid in the host immune
evasion. Thus, universal vaccine development against influenza
virus strains should focus on the HA stem region instead of
the head region.
To develop a universal influenza vaccine, Krammer et al.
(2013) designed multiple chimeric HA (cHA) constructs
combining the stem domain from the H1 strain with the
unique head domain derived from various strains. They
tested the protective potential of the cHA constructs against
multiple challenge viruses (Hai et al., 2012; Krammer et al.,
2013). Sequential vaccination with the cHA constructs in
mice elicited stem-specific polyclonal humoral responses. The
vaccination also protected mice against heterologous and
heterosubtypic influenza virus challenges (Hai et al., 2012).
Subsequent studies using female ferrets revealed that the
vaccination with cHA reduced viral titers in nasal turbinates,
lungs, and olfactory bulbs (Krammer et al., 2014). Recently,
a confirmatory study was performed in male ferrets. It was
found that live-attenuated vaccines expressing cHAs were
indeed able to confer protection during virus challenge
(Nachbagauer et al., 2018).
In a second approach, another group designed immunogens
comprising only the stem region designated as mini-HAs
(Impagliazzo et al., 2015). They constructed multiple mini-HAs
that were stable as either monomers or trimers. The mini-HAs
were found to induce high titers of antibodies binding to the HA
of group 1 (H1, H5, and H9) and group 2 (H3 and H7) influenza
A strains. The trimeric mini-HAs displayed full protection of
mice against heterosubtypic influenza challenge. In contrast,
the monomeric mini-HAs only conferred partial protection.
Consistently, monkeys vaccinated with the trimeric mini-HA had
significantly reduced fever after being challenged with the H1N1
virus. Many influenza vaccines based on the cHA and headless
HA approaches are currently undergoing clinical trials (WHO).
For instance, in an ongoing phase I clinical trial, adults aged from
18 to 39 were given a live-attenuated influenza vaccine expressing
cHA followed by an inactivated vaccine expressing another cHA
(NIH, United States).
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Multidomain Antibody to Confer
Protection Against Influenza Infection
Due to the conservation of the HA stem region, many groups
are actively developing antibodies directed toward the stem
domain (Krammer et al., 2014; He et al., 2015). The stem-specific
antibodies displayed broader specificities than the antibodies
directed toward the HA head domain (Joyce et al., 2016).
Although several of these antibodies have entered clinical
trials, their use as prophylactic agents remained elusive due to
incomplete coverage of the various influenza strains.
Laursen et al. (2018) utilized structure-based antibody design
with the aim to develop an antibody that could provide broad
and long-lasting protection against influenza A and B strains.
They designed a multidomain antibody designated as MD3606
comprising four antibodies linked to a human IgG1 Fc. The four
antibodies were SD36, SD38, SD83, and SD84. SD36 was found
to neutralize influenza A virus group 2, while SD38 was found
to neutralize both group 1 and group 2. Additionally, SD84 and
SD83 were found to neutralize all influenza B strains. Structural
analysis of these antibodies revealed that these antibodies were
able to bind to highly conserved epitopes. When administered
intravenously or expressed locally by a viral vector, MD3606 was
found to confer broad protection in mice against influenza A and
B viral infections. Further development of MD3606 is warranted
as it has the potential to confer passive protection throughout
the influenza season, provided the preclinical findings could be
replicated in clinical trials.
DENGUE VIRUS
In recent decades, dengue virus (DENV) has emerged as a
significant public health threat with an estimated 390 million
infections annually (Bhatt et al., 2013). Dengue infections
are caused by four antigenically distinct serotypes (DENV1-
4) that can cross-react with each other immunologically.
Currently, there is only one recombinant live-attenuated vaccine
(Dengvaxia) approved for dengue prevention in endemic
populations (Guy et al., 2015). However, the vaccine has low
efficacy (53%) for seronegative individuals (Hadinegoro et al.,
2015). Dengvaxia is also associated with increased risk of
hospitalization for dengue among vaccinated children from 2
to 5 years of age (Hadinegoro et al., 2015). A recent clinical
trial concluded that Dengvaxia led to increased risk of antibody-
dependent enhancement (ADE) in the seronegative individuals
(Halstead, 2017). ADE is a phenomenon in which the elicited
antibodies during primary infection are cross-reactive with the
heterologous serotypes but are non-neutralizing. The antibody-
bound virus is more easily internalized by Fcγ receptor-positive
myeloid cells, leading to infection enhancement. Thus, it is
desirable for a vaccine to induce only neutralizing antibodies but
not non-neutralizing antibodies. In the case of dengue infection,
ADE has been identified as the central mechanism associated with
dengue hemorrhagic fever and dengue shock syndrome during
secondary infections (Guzman et al., 2013). Thus, the success
of dengue vaccine design hinges on the elimination of ADE in
addition to balanced immune responses against all four serotypes.
FIGURE 3 | Resurfaced domain III of the envelope glycoprotein. Cartoon
representation of domain III of DENV2 envelope glycoprotein. The residues in
the FG loop and AB loop that were mutated in the rsDIII-Ala30 are shown as
spheres and labeled. PDB ID: 1OAN.
Masking of Non-neutralizing Epitopes
The mature virion of DENV is coated by glycoprotein E. It
contains three domains, which are domain I (EDI), domain II
(EDII), and domain III (EDIII) (Kuhn et al., 2002). EDIII is
an attractive antigen as it is targeted by broadly neutralizing
antibodies. However, previous animal studies revealed that
although immunization using EDIII proteins induced robust
antibody responses, neutralization was modest and limited to
serotype-specific responses (Hermida et al., 2006; Saejung et al.,
2007; Zhang et al., 2007; Batra et al., 2010). The presence
of non-neutralizing antibodies targeting the immunodominant
epitopes likely accounted for the limited neutralization potential
of EDIII protein (Frei et al., 2018). To address the issue, a panel
of resurfaced EDIII proteins was designed. Non-neutralizing
epitopes such as the AB loop epitope and the serotype-specific FG
loop epitope were masked in these variants (Frei et al., 2018). One
of the resurfaced EDIII designated as rsDIII-Ala30 was found to
only bind to the neutralizing antibodies 4E11 and 4E5A, but not
the non-neutralizing antibody (2H12) and the serotype-specific
antibody (3H5) (Figure 3). Upon immunization in mice, rsDIII-
Ala30 elicited broadly reactive and cross-neutralizing antibody
responses against DENV1-3. However, its antisera are insufficient
to confer protection from DENV2 infection in mice.
Structure-Based Anti-dengue
Antibody Design
Previously, antibody 4E11 was identified to neutralize dengue
viruses of all serotypes (Thullier et al., 1999, 2001; Cockburn
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et al., 2012). However, its neutralizing activity was limited,
potentially due to epitope inaccessibility on the mature virion
(Tharakaraman et al., 2013). To improve the neutralizing
potential of 4E11, Tharakaraman et al. (2013) produced a
4E11 variant designated as 4E5A that carried five amino acid
substitutions. 4E5A showed marked improvement in affinity
toward EDIII of DENV4. However, the affinity of 4E5A toward
DENV4 is modest in comparison to its affinities to other DENV
serotypes. Subsequently, they performed structural analysis to
design an antibody designated as Ab513 (Robinson et al.,
2015). This antibody differed from the starting murine antibody
4E11 through (1) six point mutations and deletion at position
26 to improve affinity toward DENVs and (2) mutations to
humanize the antibody. Challenge studies revealed that the
mice administered with Ab513 had accelerated recovery of
platelet level post-DENV challenge. Furthermore, the passively
immunized mice displayed significant reduction in the viral load
upon challenge. Currently, Ab513 is in the preclinical trial to
determine the optimal dosing scheme for use as a therapeutic or
prophylactic antibody against DENV infection.
ENTEROVIRUSES CAUSING HAND,
FOOT, AND MOUTH DISEASE
Hand, foot, and mouth disease (HFMD) is a significant public
health threat. In 2017, China experienced large-scale HFMD
outbreaks of over 1.95 million cases with 96 fatalities (WHO
Western Pacific). Besides China, HFMD outbreaks have been
occurring periodically throughout the world in countries such
as Taiwan, Japan, Vietnam, Singapore, and Malaysia. The
main etiological agents for HFMD are EV-A71 and CV-A16.
Currently, there are three licensed formaldehyde-inactivated
HFMD vaccines in China. However, these vaccines could only
confer protection at 80% efficacy against severe HFMD in
comparison to 95% efficacy against mild HFMD. In addition,
the monovalent EV-A71 vaccine is not protective against HFMD
caused by CV-A16. With the rising concern of HFMD outbreaks,
there is a need for an effective bivalent vaccine against both
EV-A71 and CV-A16.
Bivalent Hand, Foot, and Mouth
Disease Vaccine
The SP70 epitope is the main neutralizing epitope in EV-A71.
The epitope was discovered to elicit neutralizing antibodies and
conferred protection against homologous and heterologous EV-
A71 strain challenges in neonatal mice (Foo et al., 2007a,b).
The SP70 epitope lies in the GH loop of VP1 (aa208–222)
situated at the surface of the viral capsid (Plevka et al.,
2012; Lyu et al., 2015a,b). CV-A16 also possesses an amino
acid segment corresponding to the SP70 epitope (Figure 4;
Ren et al., 2013, 2015).
To develop a bivalent vaccine, Zhao et al. (2015) designed
a chimeric EV-A71 Virus-Like Particle (ChiEV-A71 VLP). The
SP70 peptide of EV-A71 was replaced with the corresponding
SP70 sequence from CV-A16 in ChiEV-A71 VLP (Zhao et al.,
2015). The VLP was found to elicit robust Th1/Th2-dependent
FIGURE 4 | VP1 of EV-A71 and CV-A16. (A,B) Cartoon representation of VP1
(amino acids 76–276) of EV-A71 (PDB ID: 3VBS) and CV-A16 (PDB ID:
5C4W). The BC loop and SP70 region are shown in black and labeled.
(C) Sequence alignment of SP70 segments of EV-A71 and CV-A16. Amino
acids that are not conserved between the two viruses are highlighted in
light gray.
immune responses against EV-A71 and CV-A16. In addition,
passive immunization with sera raised against ChiEV-A71 VLPs
conferred full protection against lethal challenge with EV-A71
and CV-A16 in neonatal mice. Structural studies revealed that
the SP70 epitope replacement converted the VLP surface charge
potential from negative to neutral (Lyu et al., 2015a). The
shift in the surface charge potential coupled with variations in
amino acid sequences most likely accounted for the additional
neutralization capability of the ChiEV-A71 VLP. Apart from
EV-A71 and CV-A16, other coxsackieviruses such as CV-A6
and CV-A10 are emerging HFMD etiological agents (Chen
et al., 2017; Anh et al., 2018). Incorporation of the neutralizing
epitopes of each virus into a single VLP will enable the
construction of a multivalent HFMD vaccine, provided the
right approaches including structural vaccinology were utilized
during vaccine design.
Improvement of Vaccine Thermostability
Despite being one of the most successful medical tools, there are
still more than 17 million vaccine-preventable deaths caused by
underutilization of vaccines (Clemens et al., 2010; Chen et al.,
2011). This situation is especially true for the poorer countries,
where cold chain is difficult to maintain, as most vaccines
are sensitive to heat. The heat-unstable vaccines have poor
efficacy when they are not properly refrigerated during delivery
and storage. This led to incomplete immunizations during the
implementation of vaccine programs (Schlehuber et al., 2011).
Self-biomineralization is one of the possible strategies to
improve vaccine stability. Biomineralization is a mechanism
where living organisms form exterior shells made of minerals
such as calcium phosphate and calcium carbonate to
cope with the harsh environments (Palmer et al., 2008;
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Farooq and Dietz, 2015). For instance, egg cells are enclosed
by mineral shells to protect themselves from the external
environment. Initially, research groups demonstrated that self-
biomineralization could be mimicked through the incorporation
of self-biomineralizing peptides (Hartgerink et al., 2001; Lee
et al., 2009). Subsequently, Wang et al. (2013) incorporated
self-biomineralizing peptides into the BC loop of attenuated
EV-A71 to improve the thermostability of the candidate vaccine
(Wang et al., 2013). From 3D structures of EV-A71, they
identified that the BC loop was externalized from the capsid and
was suitable to be the region for peptide insertion (Figure 4).
Importantly, the attenuated EV-A71 incorporated with self-
biomineralizing peptides displayed biomineralization capacity
to form 5- to 10-nm exterior shells made of calcium phosphate.
The vaccine exhibited enhanced thermostability, as it could be
stored at 26◦C for more than 9 days and at 37◦C for 1 week.
Intriguingly, they found that the biomineralized vaccine had
improved immunogenicity, indicating an additional advantage
of this approach.
STRUCTURAL VACCINOLOGY PITFALLS
Structural vaccinology has a great potential, but it faces some
limitations. Firstly, this technology is susceptible to incomplete
structural and immunological knowledge of the virus-induced
host immune responses. For instance, mapping of a dengue
epitope on available dengue structures revealed that the epitope
was inaccessible in any of the known dengue configurations
(Li et al., 2018). This indicated that the antibody recognized
an as-yet unresolved conformation of the E protein displaying
the epitope on the dengue surface. Another drawback is
the static nature of X-ray crystallographic analysis of the
antigen–antibody complexes. X-ray crystallography is one of
the most utilized structural biology technique to understand
antigen–antibody complexes (Toride and Brooks, 2018).
However, the static picture provided by X-ray crystallography
tends to obscure the role of structural plasticity in facilitating
antigen–antibody interactions (Van Regenmortel, 2016).
Generally, the structures visualized in antigen–antibody
complexes and the free molecules differed at the binding
sites due to structural alterations during binding. Therefore,
the structure of an antigen–antibody complex determined
using X-ray crystallography does not necessarily equate to
the actual immunogenic structure recognized by the B cell
receptors during antibody production. Intriguingly, it can
be noted that most of the structural vaccinology efforts
attempted to improve the B-cell antibody responses, but
not the T-cell responses. This is problematic as the T-cell
response is known to be associated with many antiviral
properties including viral clearance and decreased viremia
(Rosendahl et al., 2014). Furthermore, induction of T-cell
response negated the effect of viral mutations, ultimately
preventing them from escaping the immune responses
(Rosendahl et al., 2014).
In addition to the aforementioned pitfalls, there are
several review papers that have discussed the limitations of
structural vaccinology to develop an effective vaccine against
HIV (Pejchal and Wilson, 2010; Van Regenmortel, 2016).
These pitfalls underscore the importance of acquiring new
structural and functional insights into humoral immune
responses against pathogens. Furthermore, incorporation of
multiple structural techniques especially nuclear magnetic
resonance (NMR) is favorable to study the structure and
molecular dynamics of antigen–antibody complexes (Moraes
et al., 2016). As structural vaccinology is still developing, its
application is primarily limited to the design of recombinant
protein vaccine, peptide vaccine, and VLPs. These vaccine
platforms are associated with low immunogenicity. Therefore,
it is crucial to integrate structural vaccinology with other
complementary key technologies. For instance, DS-Cav1
protein vaccine could be integrated with the single-round
replication recombinant vesicular stomatitis virus vector to
potentially enhance its immunogenicity if required (Johnson
et al., 2013). Lastly, a structural vaccinology approach
should be extended to improve T-cell responses and not
just focus on the B-cell responses to produce better viral
vaccines in the future.
CONCLUSION
Many of the structure-based vaccine candidates are under
development, and some of them are in clinical trials (Robinson
et al., 2015; Sastry et al., 2017; Huang et al., 2018). Recent
advances have proven that structure-based vaccines are
feasible. In some cases, structural knowledge is mandatory
to circumvent the problems faced by conventional strategies.
Based on current evidence, structural knowledge is essential
to stabilize malleable antigens. It also allows the modifications
of proteins or envelopes, either to enhance antigenicity or
mask the non-neutralizing epitopes (Dey et al., 2009; de
Taeye et al., 2018; Frei et al., 2018). Moreover, structure-based
modifications are useful to lock antigenic proteins or envelopes
in a certain conformation to maximize epitope presentation
(McLellan et al., 2013a; Rutten et al., 2018). In addition,
structural vaccinology can be utilized to design antibody
therapies (Robinson et al., 2015; Huang et al., 2018). Lastly,
a structural vaccinology approach can be used to improve
vaccine thermostability, potentially solving the cold-chain
problem faced in remote and poorer areas in large continents
(Wang et al., 2013).
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